Novel Antimicrobial Agents Against Multi-drug-resistant Gram-negative Bacteria: An Overview
George Karras, Venetia Giannakaki, Vasilios Kotsis and Spiros Miyakis
Pages 175-181 (7)
No novel antimicrobial agents against multi-drug-resistant Gram-negative bacteria have been available to daily
clinical practice during the last 5 years. On the other hand, resistance rates and mechanisms of those pathogens are increasing
worldwide. Pan-resistant (against which none of the currently available antibiotics is effective) strains of Klebsiella
pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa have been described. Encouraging is the fact
that several novel compounds (some of them with mechanisms of action different to those of the antibiotics commercially
available) are through the development stages. We summarize the main such compounds that show potential for offering
solution to the treatment of Gram-negative multi-resistant bacteria along with the discussion of some patents associated
with the topic.
Antimicrobials, multidrug resistance, enterobacteriaceae, Pseudomonas aeruginosa, acinetobacter, carbapenemase, BETA-LACTAMS, BETA-LACTAMASE INHIBITORS, QUINOLONES, TETRACYCLINES
The Academic Suite, Level 8, Block C, The Wollongong Hospital, Wollongong NSW 2500, Australia.